The minimum significant ratio: A statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies

被引:91
作者
Eastwood, BJ [1 ]
Farmen, MW
Iversen, PW
Craft, TJ
Smallwood, JK
Garbison, KE
Delapp, NW
Smith, GF
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Stat & Informat Sci, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Cardiovasc Res, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Lead Optimizat Biol, Indianapolis, IN 46285 USA
关键词
minimum significant ratio; replicate-experiment studies; potency reproducibility; statistical methods;
D O I
10.1177/1087057105285611
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The authors show by illustration that procedures used to validate the reliability of single-concentration high-throughput screens such as the signal window and Z' factor do not ensure sufficient reliability in potency estimates from concentration response assays. They develop the minimum significant ratio as a statistical parameter to characterize the fold change between 2 compounds run in the same experiment that can be considered a real difference and use this parameter to characterize the reliability of the assay. They adapt methods described by Bland and Altman to develop a simple set of 2 experiments to estimate the minimum significant ratio and show that this protocol can identify assays that lack reproducibility. The methods are then extended to validate the equivalency of the same assay run by multiple laboratories.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 16 条
  • [1] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
    BLAND, JM
    ALTMAN, DG
    [J]. LANCET, 1986, 1 (8476) : 307 - 310
  • [2] Eastwood B. J, 2001, COMPUTING SCI STAT, V33, P462
  • [3] Eastwood BJ, 2005, PHARM DEV, P667, DOI 10.1002/0471728780.ch15
  • [4] Gallant A.R., 1987, NONLINEAR STAT MODEL
  • [5] 1,2-dibenzamidobenzene inhibitors of human factor Xa
    Herron, DK
    Goodson, T
    Wiley, MR
    Weir, LC
    Kyle, JA
    Yee, YK
    Tebbe, AL
    Tinsley, JM
    Mendel, D
    Masters, JJ
    Franciskovich, JB
    Sawyer, JS
    Beight, DW
    Ratz, AM
    Milot, G
    Hall, SE
    Klimkowski, VJ
    Wikel, JH
    Eastwood, BJ
    Towner, RD
    Gifford-Moore, DS
    Craft, TJ
    Smith, GF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (05) : 859 - 872
  • [6] Data concordance from a comparison between filter binding and fluorescence polarization assay formats for identification of ROCK-II inhibitors
    Hubert, CL
    Sherling, SE
    Johnston, PA
    Stancato, LF
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (04) : 399 - 409
  • [7] IVERSEN PW, IN PRESS J BIOMOL SC
  • [8] KENAKIN T, 1997, PHARMACOLOGIC ANAL D, P209
  • [9] CHOOSING NEAR-LINEAR PARAMETERS IN THE 4-PARAMETER LOGISTIC MODEL FOR RADIOLIGAND AND RELATED ASSAYS
    RATKOWSKY, DA
    REEDY, TJ
    [J]. BIOMETRICS, 1986, 42 (03) : 575 - 582
  • [10] Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors .1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation
    Sall, DJ
    Bastian, JA
    Briggs, SL
    Buben, JA
    Chirgadze, NY
    Clawson, DK
    Denney, ML
    Giera, DD
    GiffordMoore, DS
    Harper, RW
    Hauser, KL
    Klimkowski, VJ
    Kohn, TJ
    Lin, HS
    McCowan, JR
    Palkowitz, AD
    Smith, GF
    Takeuchi, K
    Thrasher, KJ
    Tinsley, JM
    Utterback, BG
    Yan, SCB
    Zhang, MS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (22) : 3489 - 3493